Allergic conjunctivitis is an inflammatory eye condition caused by an allergic reaction to airborne allergens such as pollen, dust, or pet dander. It accounts for a significant portion of ocular allergy cases, with therapies focusing on antihistamines, mast cell stabilizers, corticosteroids, and emerging biologics. As per Ke Song et al., 2025, epidemiological data indicates that allergic conjunctivitis affects approximately 15-20% of the general population in developed countries.
Major companies involved in the allergic conjunctivitis pipeline analysis include Regeneron Pharmaceuticals, Blueprint Medicines Corporation, and others.
Leading drugs currently in the pipeline include REGN5713, REGN1908, BLU-808, and others.
The allergic conjunctivitis drug pipeline shows significant growth driven by innovative biologics targeting immune pathways and novel formulations improving patient compliance. Increasing clinical trials indicate expanding therapeutic options.
The Allergic Conjunctivitis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into allergic conjunctivitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for allergic conjunctivitis. The allergic conjunctivitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The allergic conjunctivitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with allergic conjunctivitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to allergic conjunctivitis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Allergic conjunctivitis is an inflammation of the conjunctiva caused by an allergic reaction to substances like pollen, dust, or pet dander. It results in redness, itching, and watery eyes due to histamine release and immune response.
Allergic conjunctivitis treatments typically include antihistamines, mast cell stabilizers, corticosteroids, and artificial tears to relieve symptoms and reduce inflammation effectively. In April 2024, Lupin Limited received U.S. FDA approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%, a generic equivalent to Lotemax®, indicated for temporary relief of seasonal allergic conjunctivitis symptoms, reflecting growth in the allergic conjunctivitis drug pipeline.
According to Ke Song et al., 2025, allergic conjunctivitis affects approximately 15–20% of the population in developed countries. Fiza Tariq, 2025, reports that about 40% of North Americans while 20% of the global population suffer from allergies, contributing to the high incidence of allergic conjunctivitis. Key risk factors include genetics, air pollution, atopy, pollen exposure, inflammation, and pet hair, influencing the disease’s prevalence and drug development pipeline.
This section of the report covers the analysis of allergic conjunctivitis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The allergic conjunctivitis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with 50%, covers a major share of the total allergic conjunctivitis clinical trials. It is followed by phase II at 29%, phase IV at 14%, and phase I at 7%. This strong presence in advanced phases indicates promising near-term approvals, which could significantly accelerate market growth and improve patient treatment options.
The drug molecule categories covered under the allergic conjunctivitis pipeline analysis include small molecules, monoclonal antibodies, peptides, proteins, and vaccines. The allergic conjunctivitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for allergic conjunctivitis. The pipeline is segmented based on drug classes such as antihistamines, mast cell stabilizers, corticosteroids, and immunomodulators. For example, reproxalap, a novel reactive aldehyde species modulator, is under late-stage investigation for reducing ocular inflammation. Additionally, several small-molecule antihistamines and dual-action agents targeting histamine receptors and inflammatory pathways are in development.
The EMR report for the allergic conjunctivitis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed allergic conjunctivitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in allergic conjunctivitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for allergic conjunctivitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of allergic conjunctivitis drug candidates.
REGN5713-5715, sponsored by Regeneron Pharmaceuticals, is an investigational combination of two fully human monoclonal antibodies targeting allergic conjunctivitis caused by birch pollen allergy. This Phase 3 study is examining the drug’s safety and efficacy in reducing ocular allergy signs and symptoms compared to placebo. It is also evaluating side effects, drug levels in blood, and potential antibody responses that might affect treatment effectiveness.
REGN1908-1909, sponsored by Regeneron Pharmaceuticals, is currently undergoing a Phase 3 study aiming to evaluate its safety and effectiveness in reducing signs and symptoms of allergic conjunctivitis caused by cat allergy. This investigational drug is a combination of two fully human monoclonal antibodies that specifically target and block the Fel d 1 allergen, preventing allergic reactions. The study is examining the drug’s impact compared to placebo, side effects, blood levels, and immune responses.
BLU-808, sponsored by Blueprint Medicines Corporation, is currently undergoing a Phase 2a study to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in participants with ragweed-induced allergic rhinoconjunctivitis. This oral wild-type KIT inhibitor is designed to target mast cell-driven allergic responses. The study is examining BLU-808’s effectiveness in reducing symptoms following controlled ragweed pollen exposure in an allergen exposure chamber.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Allergic Conjunctivitis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for allergic conjunctivitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into allergic conjunctivitis collaborations, regulatory environments, and potential growth opportunities.
Allergic Conjunctivitis Treatment Market Report and Forecast
Upto 35% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share